Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Genelux Corporation
National Cancer Institute (NCI)
Mural Oncology, Inc
AbbVie
Sichuan Baili Pharmaceutical Co., Ltd.
Advenchen Laboratories, LLC
ImmunoGen, Inc.
Janssen Research & Development, LLC
Eli Lilly and Company